Progyny, Inc. PGNY R2K

Q: What is the current share price of Progyny, Inc. (PGNY)?

As of 2026-07-14 21:23 PDT, Progyny, Inc. (PGNY) trades at $32.36 on NasdaqGS. Its 52-week range is $16.30 to $32.36.

Q: What is the market capitalisation of PGNY?

Progyny, Inc. (PGNY) has a market capitalisation of $2.53B on NasdaqGS.

Q: What is the P/E ratio of PGNY?

PGNY trades at a trailing price-to-earnings (P/E) ratio of 42.03. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 4.71.

Q: What is the return on equity (ROE) of PGNY?

PGNY has a return on equity (ROE) of 14.94%. Its return on capital employed (ROCE) is 15.79%.

Q: Is PGNY a good stock to buy?

This page provides a data-driven analysis of Progyny, Inc. (PGNY), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Healthcare Plans · United States

https://www.progyny.com

Company Profile ↓

$32.36

+37.88% 1Y

Mkt Cap$2.53B

P/E42.03

P/B4.71

52W High$32.36

52W Low$16.30

Book Value$5.66

EPS (TTM)$0.77

Company Overview

Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services, as well as pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions. In addition, it provides assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

Why Investors Should Care

Healthy Capital Returns

Return on capital employed stands at 15.8%.

Steady Revenue Expansion

Revenue has grown at a 50.6% CAGR over the past five years.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.06.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $1.29B (+10.4% YoY); net profit $58.52M.
Trailing 12 Months Year-on-year growth — revenue +1.4%, earnings +70.6%.
5-Year Trend Long-term compounding — revenue CAGR 50.6%, profit CAGR 4.7%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	50.65%
1 Year:	1.40%

Compounded Profit Growth

5 Years:	4.72%
1 Year:	70.60%

Stock Price Performance

1 Year:	+37.88%
6 Months:	+19.90%
3 Months:	+90.58%
1 Month:	+26.16%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 100% of range

$16.30 $32.36

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
RSI (14)82.14 · Overbought

Price Performance

1M+26.16%

3M+90.58%

6M+19.90%

1Y+37.88%

Valuation vs Sector

P/E of 42.03 is above the sector median of 25.41 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Compounding revenue at 50.6% over 5 years.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

RSI at 82 suggests overbought conditions.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

42.03

Industry PE

25.41

Forward P/E

14.67

PEG Ratio

Book Value

$5.66

Price to Book

4.71

P/S

1.61

EV/EBITDA

17.24

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

50.65%

Profit 5Y

4.72%

Revenue (YoY)

1.40%

Earnings (YoY)

70.60%

Profitability & Returns

ROCE

15.79%

ROE

14.94%

ROA

9.12%

Profit Margin

5.24%

Op Margin

10.77%

Gross Margin

24.11%

EPS (Latest Qtr)

$0.29

EPS (TTM)

$0.77

Balance Sheet & Liquidity

Debt/Equity

0.06

Quick Ratio

2.07

Current Ratio

2.13

Debt

$27.28M

Total Assets

$698.34M

Current Assets

$501.55M

Working Capital

$265.81M

Ownership

Promoter Holding

1.94%

Chg in Prom Hold

-0.00%

FII / Inst Holding

112.05%

Chg in FII Hold

-0.28%

Financial Snapshot

Enterprise Value

$2.53B

Total Revenue (TTM)

$1.29B

EBITDA

$109.51M

Free Cash Flow

$200.21M

Operating Cash Flow

$206.33M

Shares Outstanding

78.33M

Gross Margin

24.11%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	PGNY Progyny, Inc. R2K	32.36	42.03	$2.53B	0.00%	15.79%	14.94%	50.65%	4.72%
2	LLY Eli Lilly and Company SPX	1,152.54	41.02	$1.03T	0.61%	-	107.46%	7.20%	11.41%
3	JNJ Johnson & Johnson SPX	253.85	29.45	$611.07B	2.23%	14.88%	26.42%	2.43%	4.76%
4	ABBV AbbVie Inc. SPX	244.78	119.40	$432.48B	3.04%	10.47%	-129.24%	1.75%	-29.06%
5	UNH UnitedHealth Group Incorporated SPX	425.19	32.02	$386.13B	2.27%	9.74%	12.18%	10.40%	5.43%
6	MRK Merck & Co., Inc. SPX	120.78	34.02	$298.31B	2.86%	-	18.94%	5.64%	10.01%
7	AZN AstraZeneca PLC NDX	164.50	24.81	$255.12B	1.77%	15.97%	23.48%	9.82%	45.96%
8	TMO Thermo Fisher Scientific Inc. SPX	534.07	29.33	$198.47B	0.40%	8.14%	13.52%	8.81%	12.95%
9	AMGN Amgen Inc. NDXSPX	355.25	24.69	$191.73B	2.84%	18.02%	101.32%	11.77%	5.58%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	122.13M	128.65M	122.28M	127.55M	172.22M	195.00M	205.37M	214.32M	258.39M	279.37M	280.89M	269.94M	278.08M	304.09M	286.62M	298.43M	324.04M	332.87M	313.35M	318.40M	328.50M
Gross Profit	3.93M	5.04M	5.05M	5.42M	9.96M	11.45M	12.32M	11.77M	16.60M	11.96M	20.84M	20.67M	28.91M	29.62M	28.49M	25.11M	32.95M	43.89M	45.99M	44.49M	58.64M	60.64M	62.62M	56.89M	62.41M	68.28M	59.24M	63.43M	75.80M	78.97M	72.83M	76.88M	83.07M
Operating Income	-1.84M	-317.00K	-587.00K	-703.00K	3.11M	2.35M	3.07M	1.14M	3.43M	-1.07M	4.83M	1.16M	11.81M	11.66M	9.06M	-188.00K	-58.00K	8.84M	11.26M	3.31M	15.01M	15.18M	18.19M	13.80M	18.52M	20.69M	12.46M	15.79M	24.17M	24.36M	21.53M	15.22M	35.38M
Net Income	4.15M	-831.00K	-1.14M	-1.52M	2.52M	1.52M	-8.21M	-4.40M	3.63M	-1.06M	4.82M	39.07M	15.17M	18.73M	16.80M	15.08M	4.97M	8.77M	13.21M	3.41M	17.68M	14.99M	15.90M	13.47M	16.90M	16.48M	10.42M	10.53M	15.06M	17.11M	13.86M	12.48M	24.23M
Diluted EPS	-	-	-	-	0.01	-	-1.10	-0.07	0.04	-0.01	0.05	0.39	0.15	0.19	0.17	0.15	0.05	0.09	0.13	0.03	0.18	0.15	0.16	0.13	0.17	0.17	0.11	0.12	0.17	0.19	0.15	0.14	0.29
R&D Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.50M	-	2.60M	-	2.80M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	48.58M	105.40M	229.68M	344.86M	500.62M	786.91M	1.09B	1.17B	1.29B
Gross Profit	7.40M	19.43M	45.51M	70.06M	112.14M	167.32M	238.80M	253.36M	304.48M
Operating Income	-11.01M	-3.45M	9.68M	8.35M	32.34M	23.34M	62.18M	67.45M	85.28M
Net Income	-12.45M	661.00K	-8.57M	46.46M	65.77M	30.36M	62.04M	54.34M	58.52M
Diluted EPS	-2.37	0.04	-0.41	0.47	0.66	0.30	0.62	0.57	0.65
R&D Expense	-	-	-	-	-	-	-	-	9.50M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	41.32M	150.43M	253.93M	358.06M	542.99M	756.62M	607.10M	742.43M
Total Equity	-97.62M	-95.11M	114.27M	166.95M	251.82M	376.97M	553.43M	422.06M	516.04M
Cash & Equivalents	-	127.00K	80.38M	70.31M	91.41M	120.08M	97.30M	162.31M	112.24M
Total Liabilities	-	30.20M	36.16M	86.98M	106.24M	166.02M	203.19M	185.04M	226.39M
Current Liabilities	-	30.20M	36.16M	77.79M	98.82M	159.54M	185.95M	168.63M	202.39M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-9.47M	2.27M	-1.53M	36.20M	26.04M	80.39M	188.81M	179.10M	210.19M
Investing Cash Flow	-612.00K	1.90M	-2.76M	-40.03M	8.77M	-43.87M	-200.53M	195.79M	-159.01M
Financing Cash Flow	11.77M	-8.74M	84.55M	-6.25M	-13.70M	-7.86M	-11.07M	-309.88M	-99.36M
Capital Expenditure	-612.00K	-579.00K	-2.96M	-1.04M	-2.13M	-3.24M	-3.64M	-5.41M	-18.41M
Free Cash Flow	-10.09M	1.69M	-4.49M	35.17M	23.91M	77.15M	185.17M	173.70M	191.78M
Share Buybacks	-	1.21M	185.00K	-	-	0	0	300.28M	81.66M

Ratios (Annual)

Figures in %.

Metric	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	15.2%	18.4%	19.8%	20.3%	22.4%	21.3%	21.9%	21.7%	23.6%
Operating Margin %	-22.7%	-3.3%	4.2%	2.4%	6.5%	3.0%	5.7%	5.8%	6.6%
Net Margin %	-25.6%	0.6%	-3.7%	13.5%	13.1%	3.9%	5.7%	4.7%	4.5%
ROE %	12.8%	-0.7%	-7.5%	27.8%	26.1%	8.1%	11.2%	12.9%	11.3%
ROCE %	-	-31.0%	8.5%	4.7%	12.5%	6.1%	10.9%	15.4%	15.8%

Shareholding Pattern

Insiders

1.94%

Institutions

112.05%

Public Float

114.27%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	15.32%	12.00M	$369.73M
2	FMR, LLC	8.30%	6.50M	$200.32M
3	Vanguard Portfolio Management LLC	6.76%	5.29M	$163.07M
4	Vanguard Capital Management LLC	4.44%	3.48M	$107.28M
5	State Street Corporation	3.93%	3.08M	$94.92M
6	Ameriprise Financial, Inc.	3.61%	2.83M	$87.06M
7	Fort Washington Investment Advisors, Inc.	3.44%	2.69M	$83.00M
8	Wellington Management Group, LLP	2.92%	2.29M	$70.49M
9	Morgan Stanley	2.92%	2.29M	$70.49M
10	Soleus Capital Management, L.P.	2.64%	2.07M	$63.69M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for PGNY

Google News ue, 14 Jul 2026

Progyny, Inc. (PGNY) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxQZVVDbXE2cklrSlVZd3B2QUxBV0Z6SS1mX2xta1d1UDhfVmhYS3VuWmdSQzAtejYzaTdKSUprRHB2MktoZ0FzTUVBTlc4VDRaVDhUemNBY29CZGJURFc5UHlwajluNHlDdGd2d0s2VHhUaU9Pdi1DZ2ZYSW90WmIzdDN1Q2M2UHVDeXNENk…

Google News Mon, 13 Jul 2026

Progyny (PGNY) Stock Is Up, What You Need To Know - StockStory

<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxNSklKa2UzYVJtRXJnRC1CeWtveGk1LWFmNU1TNG85WF9zcU9zTUozOTJhUWQ2S21KZ0tSN3NZeHdyRTQ1M3E4WEo0OGczRDFQd1NVZ3ZBTE1RcF9CVzF4OEtXeWdfYTdZRTJLZ2M5bFctdzhiVmlYTlJBN1Vjcm55Sk1oeUt0VmtSdnNNb0…

Google News ue, 14 Jul 2026

[144] Progyny, Inc. SEC Filing - Stock Titan

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxOMEYxckRLWllEZ19xMFJSRzItb1VMTUpsczFtaExlV1ZhNTZsM2l4bjJhNzluODF1YXBBWjBHUVBqNjdBdmI1bzFyZ0M4VnRxT1lJOTNTUGZmekMxU1lRTk5XV0pfWFRSU3N6bzFFM2V3S2FFUzZkdGRYZGVvMl83NUxlRklURWxURDVmdT…

Google News hu, 25 Jun 2026

PGNY Forecast — Price Target — Prediction for 2027 - TradingView

<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1UNWYxczl2SkNuWmNBQWxHeXM2b2RvbW9DdXdZVEpXWnRYNEphR0ZPY3V6X0lLYlp4WUFpczE5SWlRcFI2QjZPSFE2ZXJWb2RSVUpicm1Nd1BoMFozUmhnbEFKazVIMVI4eVFERHJ2UVB6Qk1MMUl0cVZB?oc=5" target="_blank">PGN…

Google News Mon, 13 Jul 2026

PGNY Maintained by Keybanc -- Price Target Raised to $35.00 - GuruFocus

<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxNZURWRV9RdmJTVmFWWXRtcml6THdLNWRhWWlOeGloX1Z3a0VLcVdTaTBBUXlZUm83azZfbXFVRFBrTm1NQS15b2JBOUhqanBKZ2xMQks1XzZOLU9YVWhQdlFNZkVoOHR2dzBTSzY4amhreUdHWmR0QWgzd2xNZVNnMWpLdTN2dkxncU83UF…

Google News Mon, 13 Jul 2026

(PGNY) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily

<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxNZlh0aGIyYjNIZF9YanhINGJPa0s3d2R4WFlmYmEzWjRNbS15TnVuSndPYkJkbHl6VFRzMlFqNFoxOTZrRUwxMkRRcm9OM1gyY2c5TlZiX0RDNkhUZENNRXBtbkhNTXVpOEU5c2I3aTJfMTl4RllvTUJyRkd4cXhRUTl5MXB0VUV6bVN1MU…

PGNY — Frequently Asked Questions

What is the current share price of Progyny, Inc. (PGNY)?

As of 2026-07-14 21:23 PDT, Progyny, Inc. (PGNY) trades at $32.36 on NasdaqGS. Its 52-week range is $16.30 to $32.36.

What is the market capitalisation of PGNY?

Progyny, Inc. (PGNY) has a market capitalisation of $2.53B on NasdaqGS.

What is the P/E ratio of PGNY?

PGNY trades at a trailing price-to-earnings (P/E) ratio of 42.03. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 4.71.

What is the return on equity (ROE) of PGNY?

PGNY has a return on equity (ROE) of 14.94%. Its return on capital employed (ROCE) is 15.79%.

Is PGNY a good stock to buy?

This page provides a data-driven analysis of Progyny, Inc. (PGNY), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Progyny, Inc. PGNY R2K

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Progyny, Inc. (PGNY) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance

Progyny (PGNY) Stock Is Up, What You Need To Know - StockStory

[144] Progyny, Inc. SEC Filing - Stock Titan

PGNY Forecast — Price Target — Prediction for 2027 - TradingView

PGNY Maintained by Keybanc -- Price Target Raised to $35.00 - GuruFocus

(PGNY) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily

PGNY — Frequently Asked Questions

What is the current share price of Progyny, Inc. (PGNY)?

What is the market capitalisation of PGNY?

What is the P/E ratio of PGNY?

What is the return on equity (ROE) of PGNY?

Is PGNY a good stock to buy?

Explore More